This acquisition positions Mankind Pharma as a key player in the Indian women’s health and fertility drug market, while also granting the company access to high entry barrier products in the critical care segment, backed by BSV's established research and development (R&D) capabilities
Read More
Mankind Pharma has announced that its board of directors will convene on September 24, 2024, to discuss and potentially approve a proposal to raise funds through the issuance of various securities. The company is considering multiple options, including non-convertible debentures, commercial papers, and other forms of debt securities, according to a regulatory filing.
Read More
In Q4 FY24, Mankind Pharma reported revenue from operations of Rs 2,441 Cr, marking a notable 19 per cent year-on-year (YoY) increase
Read More
